Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to observe in a randomized prospective study the effectiveness and toxicity of Thymoglobulin vs. Campath-1H used for induction therapy in recipients of living donor (LD) kidneys, compared with the investigators standard treatment protocol of Zenapax® and maintenance immunosuppression.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Miami
• Collaborator: Hoffmann-La Roche
• Treatments: Alemtuzumab; Antilymphocyte Serum; Calcineurin Inhibitors; Daclizumab; Thymoglobulin

Criteria

Inclusion Criteria:

• Age >14 years

• Weight >40 kg

• Primary renal allograft:living related (non HLA identical) and unrelated donor

• Negative standard cross match for T-cells

• Signed and dated consent form

Exclusion Criteria:

• Patient has previously received or is receiving an organ transplant other than kidney

• Patient has received a kidney transplant from a non-heart beating donor

• Patient has received an ABO incompatible donor kidney

• Recipient or donor is seropositive for human immunodeficiency virus (HIV)

• Patient has a current malignancy or a history of malignancy